Takeda’s Zasocitinib Significantly Outperforms Deucravacitinib in Head-to-Head Phase 3 Psoriasis Study, Promising to Redefine Oral Treatment Expectations

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/8/2026

1. HUVR:IN
2. TAP
3. DELL
4. ROIV
5. ANET
6. NKE
7. PANW
8. CL
9. SNDK
10. SPG

Go back to Takeda’s Zasocitinib Significantly Outperforms Deucravacitinib in Head-to-Head Phase 3 Psoriasis Study, Promising to Redefine Oral Treatment Expectations
(NYSE: TAK) Delayed: 18.45 -0.26 (1.39%)
Previous Close $18.71    52 Week High $0.55 
Open $18.48    52 Week Low $0.55 
Day High $18.54    P/E N/A 
Day Low $18.39    EPS $-0.20 
Volume 1,499,548